REFERENCES

1. Lippi G, Favaloro EJ, Franchini M, Guidi GC. Milestones and perspectives in coagulation and hemostasis. Semin Thromb Hemost. 2009;35(1):9-22. doi:10.1055/s-0029-1214144

2. Kirkwood TB.

3. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 25 2009;113(26):6511-6521. doi:10.1182/blood-2009-01-129155

4. Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. American Journal of Hematology. 2010;85(3):174-180. doi:10.1002/ajh.21616

5. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580- 587. doi:10.1056/NEJMra066469

6. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866. doi:10.1182/bloodadvances.2019000966

7. Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016;127(3):296- 302; quiz 370. doi:10.1182/blood-2015-07-659656

8. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395-403. doi:10.1016/S0140-6736(08)60203-2

9. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393- 402. doi:10.1016/S0140-6736(10)60959-2

10. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.

11. Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. AmJHematol. 2018;93(7):921-930. doi:10.1002/ajh.25125

12. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005;3(7):1432-1436. doi:10.1111/j.1538-7836.2005.01436.x

13. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578- 1584. doi:10.1056/NEJM199811263392202

14. George JN. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (Experience of the Oklahoma TTP-HUS Registry, 1989-2007). Kidney Int Suppl. 2009;2009(112):S8-S10. doi:10.1038/ki.2008.609

15. Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157-e164. doi:10.1016/S2352-3026(17)30026-1

16. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2496-2502. doi:10.1111/jth.15010

17. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836-2846. doi:10.1182/blood-2016-10-709857

18. Zwicker JI, Muia J, Dolatshahi L, et al. Adjuvant low-dose rituximab and plasma exchange for acquired TTP. Blood. 2019;134(13):1106-1109. doi:10.1182/blood.2019000795

19. Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura.

20. Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. NEngl JMed. 2019;380(4):335-346. doi:10.1056/NEJMoa1806311

21. Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87(5):1061-1073. doi:10.1038/ki.2014.423

22. Shen YM, Wolfe H, Barman S. Evaluating thrombocytopenia during heparin therapy. JAMA. 2018;319(5):497-498. doi:10.1001/jama.2017.21898

23. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759-765. doi:10.1111/j.1538-7836.2006.01787.x

24. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489

25. Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011;9(12):2389-2396. doi:10.1111/j.1538- 7836.2011.04487.x

26. Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood. 2017;130(9):1104-1113. doi:10.1182/blood- 2017-04-778993

TJ. Loren AW, Abrams CS. Efficacy of HPA-1a (PlA1)-negative platelets in a patient with post­

transfusion purpura. Am JHematol. 2004;J6(3):258-262. doi:10.1002/ajh.20093

28. George JN. Platelets. Lancet. 2000;355(9214):1531-1539. doi:10.1016/S0140-6J36(00)021J5-9

29. Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma.

30. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15. doi:10.1038/s41408-018-0054-y

31. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-5133; quiz 5252. doi:10.1182/blood-2012-0J-44406J

32. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. NEngl JMed. 2005;353(1):33-45. doi:10.1056/NEJMoa043800

33. Basila D, Yuan CS. Effects of dietary supplements on coagulation and platelet function. Thromb Res. 2005;11J(1-2):49-53; discussion 65-J. doi:10.1016/j.thromres.2005.04.01J

34. Fernandez F, Goudable C, Sie P, et al. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br JHaematol. 1985;59(1):139-148. doi:10.1111/j.1365- 2141.1985.tb029J4.x

35. Vigano G, Benigni A, Mendogni D, Mingardi G, Mecca G, Remuzzi G. Recombinant human erythropoietin to correct uremic bleeding. Am J Kidney Dis. 1991;18(1):44-49. doi:10.1016/s02J2-6386(12)80289-J

36. Bidlingmaier C, Deml MM, Kurnik K. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections. Haemophilia. 2006;12(3):212-21J. doi:10.1111/j.1365-2516.2006.0121J.x

3J. Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105(3):545-553. doi:10.3324/haematol.2019.232132

38. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012;3J9(9824):144J-1456. doi:10.1016/S0140-6J36(11)61139-2

39. Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 200J;109(2):546-551.

40. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. NEngl JMed. 201J;3JJ(9):809-818. doi:10.1056/NEJMoa1J03068

41. Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021;13J(16):2231-2242. doi:10.1182/blood.202000921J

42. James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280-300. doi:10.1182/bloodadvances.2020003265

43. Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease. Blood. 2009;114(6):1158-1165. doi:10.1182/blood-2009-01-153296

44. Drebes A, de Vos M, Gill S, et al. Prothrombin complex concentrates for coagulopathy in liver disease: single-center, clinical experience in 105 patients. Hepatol Commun. 2019;3(4):513-524. doi:10.1002/hep4.1293

45. Bosch J, Thabut D, Albillos A, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology. 2008;4J(5):1604-1614. doi:10.1002/hep.22216

46. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2QQ9;145(1):24-33. doi:1Q.1111/j.1365-2141.2QQ9.Q76QQ.x

47. Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2Q15;21(2):162-17Q. doi:1Q.1111/hae.12627

48. Franchini M, Mannucci PM. Inhibitor eradication with rituximab in haemophilia: where do we stand? Br J Haematol. 2Q14;165(5):6QQ-6Q8. doi:1Q.1111/bjh.12829

49. Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A: results from the European acquired haemophilia Registry (EACH2).

5Q. Jimenez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2Q1Q;17Q(15):1383-1389. doi:1Q.1QQ1/archinternmed.2Q1Q.199

51. den Exter PL, van Es J, Klok FA, et al. Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood. 2Q13;122(7):1144-1149; quiz 1329. doi:1Q.1182/blood-2Q13-Q4-497545

52. Zondag W, Kooiman J, Klok FA, Dekkers OM, Huisman MV Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J. 2Q13;42(1):134-144. doi:1Q.1183/Q9Q31936.QQQ93712

53. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2Q18;379(13):129Q. doi:1Q.1Q56/NEJMc18Q8253

54. Favaloro EJ. Coagulation mixing studies: utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests. Am JHematol. 2Q2Q;95(1):117- 128. doi:1Q.1QQ2/ajh.25669

55. Freund Y, Cachanado M, Aubry A, et al. Effect of the pulmonary embolism rule-out criteria on subsequent thromboembolic events among low-risk emergency department patients: the PROPER randomized clinical trial. JAMA. 2Q18;319(6):559-566. doi:1Q.1QQ1/jama.2Q17.219Q4

56. van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet. 2Q17;39Q(1QQ91):289-297. doi:1Q.1Q16/SQ14Q-6736(17)3Q885-1

57. Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997;35Q(9Q94):1795-1798. doi:1Q.1Q16/SQ14Q- 6736(97)Q814Q-3

58. Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med. 2QQ1;135(2):98-1Q7. doi:1Q.7326/QQQ3-4819-135-2-2QQ1Q717Q-QQQ1Q

59. Douma RA, Mos IC, Erkens PM, et al. Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study. Ann Intern Med. 2Q11;154(11):7Q9-718. doi:1Q.7326/QQQ3-4819-154-11-2Q11Q6Q7Q-QQQQ2

6Q. Righini M, Le Gal G, Aujesky D, et al. Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. Lancet. 2QQ8;371(9621):1343-1352. doi:1Q.1Q16/SQ14Q-6736(Q8)6Q594-2

61. Stein PD, Hull RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med. 2QQ4;14Q(8):589-6Q2. doi:1Q.7326/QQQ3-4819-14Q-8-2QQ4Q42QQ-QQQQ5

62. De Pooter N, Brionne-Francois M, Smahi M, Abecassis L, Toulon P. Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in patients with non-high pre-test probability: clinical performance and cost-effectiveness analysis. J Thromb Haemos. 2021;19(5):1271-1282. doi:10.1111/jth.15278

63. Lee AY, Julian JA, Levine MN, et al. Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med. 1999;131(6):417-423. doi:10.7326/0003-4819-131-6-199909210-00004

64. Goldstein NM, Kollef MH, Ward S, Gage BF. The impact of the introduction of a rapid D-dimer assay on the diagnostic evaluation of suspected pulmonary embolism. Arch Intern Med. 2001;161(4):567-571. doi:10.1001/archinte.161.4.567

65. Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311(11):1117-1124. doi:10.1001/jama.2014.2135

66. Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed—American College of chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e351S-e418S. doi:10.1378/chest.11-2299

67. Tapson VF, Carroll BA, Davidson BL, et al. The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. Am J Respir Crit Care Med. 1999;160(3):1043-1066. doi:10.1164/ajrccm.160.3.16030

68. Decousus H, Quere I, Presles E, et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med. 2010;152(4):218- 224. doi:10.7326/0003-4819-152-4-201002160-00006

69. Cronin P, Dwamena BA. A clinically Meaningful interpretation of the prospective investigation of pulmonary embolism diagnosis (PIOPED) II and III Data. Acad Radiol. 2018;25(5):561-572. doi:10.1016/j.acra.2017.11.014

70. Anderson DR, Kahn SR, Rodger MA, et al. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA. 2007;298(23):2743-2753. doi:10.1001/jama.298.23.2743

71. Investigators P. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA. 1990;263(20):2753-2759. doi:10.1001/jama.1990.03440200057023

72. Carrier M, Lazo-Langner A, Shivakumar S, et al. Screening for occult cancer in unprovoked venous thromboembolism. NEngl JMed. 2015;373(8):697-704. doi:10.1056/NEJMoa1506623

73. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320-328. doi:10.1111/jth.12485

74. Duffett L, Castellucci LA, Forgie MA. Pulmonary embolism: update on management and controversies. BMJ. 2020;370:m2177. doi:10.1136/bmj.m2177

75. Gage BF, Bass AR, Lin H, et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial. JAMA. 2017;318(12):1115-1124. doi:10.1001/jama.2017.11469

76. Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. NEngl JMed. 2010;363(17):1608-1620. doi:10.1056/NEJMoa1002617

77. Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2(22):3317-3359. doi:10.1182/bloodadvances.2018024802

78. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed—American College of chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e24S-e43S. doi:10.1378/chest.11-2291

79. ACTIV-4a Investigators, REMAP-CAP Investigators, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. NEngl JMed. 2021;385(9):790-802. doi:10.1056/NEJMoa2105911

80. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974. doi:10.1182/bloodadvances.2020003442

81. Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545-e608. doi:10.1016/j.chest.2021.07.055

82. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153. doi:10.1056/NEJMoa025313

83. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. NEngl JMed. 2020;382(17):1599-1607. doi:10.1056/NEJMoa1915103

84. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. NEngl JMed. 2018;378(7):615-624. doi:10.1056/NEJMoa1711948

85. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clini Oncol. 2018;36(20):2017-2023. doi:10.1200/JC0.2018.78.8034

86. Kahale LA, Hakoum MB, Tsolakian IG, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;6:CD006650. doi:10.1002/14651858.CD006650.pub5

87. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140(11):867-873. doi:10.7326/0003-4819-140-11-200406010-00007

88. Schindewolf M, Steindl J, Beyer-Westendorf J, et al. Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia. J Am Coll Cardiol. 2017;70(21):2636-2648. doi:10.1016/j.jacc.2017.09.1099

89. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed—American College of chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e495S- e530S. doi:10.1378/chest.11-2303

90. Kiser TH, Burch JC, Klem PM, Hassell KL. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2008;28(9):1115-1124. doi:10.1592/phco.28.9.1115

91. Bottiger BW, Bode C, Kern S, et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. Lancet. 2001;357(9268):1583-1585. doi:10.1016/S0140-6736(00)04726-7

92. Stevens SM, Woller SC, Baumann Kreuziger L, et al. Executive summary: antithrombotic therapy for VTE disease - second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):2247-2259. doi:10.1016/j.chest.2021.07.056

93. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026

94. Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014;311(23):2414-2421. doi:10.1001/jama.2014.5990

95. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. NEngl JMed. 2014;370(15):1402-1411. doi:10.1056/NEJMoa1302097

96. Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. NEngl JMed. 2017;377(23):2240-2252. doi:10.1056/NEJMoa1615066

97. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738. doi:10.1182/bloodadvances.2020001830

98. Simes J, Becattini C, Agnelli G, et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014;130(13):1062-1071. doi:10.1161/CIRCULATIONAHA.114.008828

99. Becattini C, Agnelli G. Aspirin for prevention and treatment of venous thromboembolism. Blood Rev. 2014;28(3):103-108. doi:10.1016/j.blre.2014.03.003

100. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. NEngl JMed. 2017;376(13):1211-1222. doi:10.1056/NEJMoa1700518

101. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. NEngl J Med. 2013;368(8):699-708. doi:10.1056/NEJMoa1207541

102. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. NEngl JMed. 2013;368(8):709-718. doi:10.1056/NEJMoa1113697

103. Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-thrombotic

syndrome: a randomised placebo-controlled trial. Lancet. 2014;383(9920):880-888. doi:10.1016/S0140-6736(13)61902-9

104. Klemen ND, Feingold PL, Hashimoto B, et al. Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis. Lancet Haematol. 2020;7(8):e583-e593. doi:10.1016/S2352-3026(20)30211-8

105. Mathew TC, Ramsaran EK, Aragam JR. Impending paradoxic embolism in acute pulmonary embolism: diagnosis by transesophageal echocardiography and treatment by emergent surgery. Am Heart J. 1995;129(4):826-827. doi:10.1016/0002-8703(95)90337-2

106. Chartier L, Bera J, Delomez M, et al. Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients. Circulation. 1999;99(21):2779- 2783. doi:10.1161/01.cir.99.21.2779

107. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. NEngl JMed. 2015;373(9):823-833. doi:10.1056/NEJMoa1501035

108. Schulman S, Hwang HG, Eikelboom JW, Kearon C, Pai M, Delaney J. Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial. J Thromb Haemost. 2014;12(8):1254-1259. doi:10.1111/jth.12613

109. Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMAIntern Med. 2019;179(11):1469-1478. doi:10.1001/jamainternmed.2019.2431

110. Kucher N. Clinical practice. Deep-vein thrombosis of the upper extremities. NEngl J Med. 2011;364(9):861-869. doi:10.1056/NEJMcp1008740

111. Chopard R, Albertsen IE, Piazza G. Diagnosis and treatment of lower extremity venous thromboembolism: a review. JAMA. 2020;324(17):1765-1776. doi:10.1001/jama.2020.17272

112. Beyer-Westendorf J, Schellong SM, Gerlach H, et al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol.

2017;4(3):e105-e113. doi:10.1016/S2352-3026(17)30014-5

113. Di Nisio M, Wichers I, Middeldorp S. Treatment of lower extremity superficial thrombophlebitis. JAMA. 2018;320(22):2367-2368. doi:10.1001/jama.2018.16623

114. Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2011;364(4):351-360. doi:10.1056/NEJMra0910203

115. Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. NEngl J Med. 2013;369(4):330-340. doi:10.1056/NEJMoa1209655

116. Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med. 2009;150(5):293-300. doi:10.7326/0003-4819-150-5-200903030-00005

117. Gunther KE, Conway G, Leibach L, Crowther MA. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INRgt;10. Thromb Res. 2004;113(3-4):205-209.

doi: 10.1016/j.thromres.2004.03.004

118. Sarode R, Milling TJ, Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234-1243. doi:10.1161/CIRCULATIONAHA.113.002283

119. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. NEngl JMed. 2010;363(19):1791-1800. doi:10.1056/NEJMoa1006221

120. Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med. 2003;28(3):172-197. doi:10.1053/rapm.2003.50046

121. Frontera JA, Lewin JJ, IIIrd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: executive summary. A statement for healthcare professionals from the neurocritical care society and the society of critical care medicine. Crit Care Med. 2016;44(12):2251-2257. doi:10.1097/CCM.0000000000002057

122. Pollack CV, Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal—full cohort analysis. NEngl JMed. 2017;377(5):431-441. doi:10.1056/NEJMoa1707278

123. Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. NEngl JMed. 2019;380(14):1326-1335. doi:10.1056/NEJMoa1814051

124. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo- controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573-1579. doi:10.1161/CIRCULATIONAHA.111.029017

125. Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet. 2011;378(9785):41-48. doi:10.1016/S0140-6736(11)60824-6